Optimizing Therapeutic Strategies for Multiple Sclerosis in Italy: A Budget Impact Analysis

Author(s)

Cataldo Procacci, MSc1, Serena Gaballo, MSc2, Massimiliano Povero, PhD3.
1Azienda Sanitaria Locale, BT, Italy, 2Novartis, Milano, Italy, 3Researcher, AdRes, Turin, Italy.
OBJECTIVES: Multiple sclerosis (MS) places a considerable burden on both patients and the Italian National Health Service (NHS). This analysis aims to explore the potential economic and clinical impact of optimizing the use of currently available therapies in the Italian setting.
METHODS: A budget impact analysis was carried out from the perspective of the Italian NHS over a three-year time horizon. The number of patients expected to receive treatment each year was estimated based on national population data and MS prevalence. The current treatment landscape was compared with a more efficient scenario involving increased use of ofatumumab (+5% every year), and generics/biosimilars (+30% every year). The analysis included drug acquisition and administration costs, as well as expenses related to monitoring and managing adverse events. An additional analysis focusing on allocative efficiency (in terms of reduced administration time with ofatumumab) was conducted.
RESULTS: Over the next three years, approximately 262,000 MS patients are expected to receive treatment. Under the current scenario, the estimated total cost to the NHS is around €4.15 billion (drug costs account for 95.3% of total expenses). The alternative scenario could generate savings of about €403 million (-9.79%): €382 million in drug acquisition (-9.73%), and €21 million for administration, monitoring, and managing of adverse events (-11.03%). Such savings could allow an additional 6,613 patients per year to access high-efficacy therapies, potentially. Moreover, the optimized approach would reduce hospital and healthcare professional time by around 15%.
CONCLUSIONS: A more efficient allocation of available therapies could reduce the economic burden on the healthcare system and improve patient access to effective treatments.

Conference/Value in Health Info

2025-11, ISPOR Europe 2025, Glasgow, Scotland

Value in Health, Volume 28, Issue S2

Code

EE602

Topic

Economic Evaluation, Health Policy & Regulatory, Organizational Practices

Topic Subcategory

Budget Impact Analysis

Disease

Neurological Disorders

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×